Immunological Reviews

Tumor immunology top 10 list
pp. 5-8(4)
Author: Finn, Olivera J.

Engineering therapeutic monoclonal antibodies
pp. 9-27(19)
Authors: Liu, Xiao-yun; Pop, Laurentiu M.; Vitetta, Ellen S.

Strategies and challenges in eliciting immunity to melanoma
pp. 28-42(15)
Authors: Ferguson, Andrew R.; Nichols, Lisa A.; Zarling, Angela L.; Thompson, Elizabeth D.; Brinkman, C. Colin; Hargadon, Kristian M.; Bullock, Timothy N.; Engelhard, Victor H.

Antigen-specific immunotherapy of cervical and ovarian cancer
pp. 43-69(27)
Authors: Hung, Chien-Fu; Wu, T. C.; Monie, Archana; Roden, Richard

Immunotherapy of malignant brain tumors
pp. 70-100(31)
Authors: Mitchell, Duane A.; Fecci, Peter E.; Sampson, John H.

The impact of T-cell immunity on ovarian cancer outcomes
pp. 101-116(16)
Author: Nelson, Brad H.

Oral DNA vaccines target the tumor vasculature and microenvironment and suppress tumor growth and metastasis
pp. 117-128(12)
Authors: Xiang, Rong; Luo, Yunping; Niethammer, Andreas G.; Reisfeld, Ralph A.

Multiple roles for CD4⁺ T cells in anti-tumor immune responses
pp. 129-144(16)
Authors: Kennedy, Richard; Celis, Esteban

Polarized immune responses differentially regulate cancer development
pp. 145-154(10)
Authors: Johansson, Magnus; DeNardo, David G.; Coussens, Lisa M.

The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance
pp. 155-161(7)
Authors: Allavena, Paola; Sica, Antonio; Garlanda, Cecilia; Mantovani, Alberto

Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells
pp. 162-179(18)
Authors: Marigo, Ilaria; Dolcetti, Luigi; Serafini, Paolo; Zanovello, Paola; Bronte, Vincenzo

Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives
pp. 180-191(12)
Authors: Rodríguez, Paulo C.; Ochoa, Augusto C.

Signaling defects in anti-tumor T cells
pp. 192-205(14)
Authors: Frey, Alan B.; Monu, Ngozi

Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape
pp. 206-221(16)
Authors: Katz, Jessica B.; Muller, Alexander J.; Prendergast, George C.

Is interleukin-1 a good or bad `guy' in tumor immunobiology and immunotherapy?
pp. 222-241(20)
Authors: Apte, Ron N.; Voronov, Elena

Cancer vaccines for established cancer: how to make them better?
pp. 242-255(14)
Authors: Andrews, Daniel M.; Maraskovsky, Eugene; Smyth, Mark J.

Reengineering dendritic cell-based anti-cancer vaccines
pp. 256-276(21)
Authors: Koski, Gary K.; Cohen, Peter A.; Roses, Robert E.; Xu, Shuwen; Czerniecki, Brian J.

The promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer
pp. 277-286(10)
Author: Lynch, David H.

Enhancing the clinical activity of granulocyte-macrophage colony-stimulating factor-secreting tumor cell vaccines
pp. 287-298(12)
Authors: Jinushi, Masahisa; Hodi, F. Stephen; Dranoff, Glenn

Tumor necrosis factor-mediated interactions between inflammatory response and tumor vascular bed
pp. 299-315(17)
Authors: ten Hagen, Timo L. M.; Seynhaeve, Ann L. B.; Eggermont, Alexander M. M.

A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting
pp. 316-327(12)
Authors: Gray, Andrew; Raff, Adam B.; Chiriva-Internati, Maurizio; Chen, Si-Yi; Kast, W. Martin

Autoantibodies to tumor-associated antigens: reporters from the immune system
pp. 328-340(13)
Authors: Tan, Eng M.; Zhang, Jianying

The flip side of immune surveillance: immune dependency
pp. 341-356(16)
Authors: Prehn, Richmond T.; Prehn, Liisa M.

Twelve immunotherapy drugs that could cure cancers
pp. 357-368(12)
Author: Mac' Cheever, Martin A.